Novartis Goes All In On A Second Long-Term Bet With IFM
Pays $90m Up Front For IFM Due
Deal Snapshot: Novartis partnered with IFM Due in 2019 and has now exercised an option to buy the IFM Therapeutics subsidiary, continuing its ongoing relationship with the group.
